*The 140 mg Q2W dose is suitable for all patients except those with HoFH or on apheresis. In adults and adolescents aged 12 years and over with HoFH, the initial
recommended dose is 420 mg QM. After 12 weeks of treatment, dose frequency can be up-titrated to 420 mg Q2W if a clinically meaningful response is not achieved.
Patients on apheresis may initiate treatment with 420 mg Q2W to correspond with their apheresis schedule. †In the study, 2690 recent MI patients received Repatha®, 2254 of whom achieved LDL-C levels <55 mg/dl. ‡25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; ASCVD = Atherosclerotic cardiovascular disease; CV = Cardiovascular; EAS = European Atherosclerosis Society; ESC = European
Society of Cardiology; EVOPACS = EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes; HoFH = Homozygous familial hypercholesterolaemia; LDL-C = Low-density lipoprotein cholesterol; MI = Myocardial infarction; PCSK9 = Protein convertase subtilisin/kexin type 9;Q2W = Every 2 weeks; QM = Every month; RRR = Relative risk reduction; SC = Subcutaneously
Repatha® (evolocumab) Summary of Product Characteristics. Last revised: 31 March 2021.
Giugliano RP, et al. Lancet. 2012;380:2007-17.
Gencer B, et al. JAMA Cardiol. 2020;5(8):1-6. Main paper & Supplementary appendix.